semaglutide fda changes just got FDA-approved for kidney disease. This everything., January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in FDA Clears Semaglutide For Cardiac

This warning does not apply to Hashimotos thyroiditis or hypothyroidism caused by autoimmune or primary thyroid dysfunction

Increased thirst is not listed amongst the common adverse effects in the Summary of Product Characteristics (SmPC) approved by the MHRA, though some patients do report experiencing thirst during treatment

However, research shows that, over time, that gap narrows

Accessed 20 June 2024

Video Abstract Budget impact of oral semaglutide intensification versus sitagliptin among US patients with type 2 diabetes mellitus uncontrolled with metformin Similar content being viewed by others 1 Introduction Type 2 diabetes mellitus (T2DM) is a multifactorial disease characterized by an increased risk of obesity, macrovascular conditions such as cardiovascular disease, and microvascular disease that can lead to kidney failure, neuropathy, and blindness [1]